Literature DB >> 6648374

Determination of IgG, IgM and IgA antibody responses in human toxoplasmosis by enzyme-linked immunosorbent assay (ELISA).

H Turunen, K A Vuorio, P O Leinikki.   

Abstract

A 4-layer modification of ELISA for the determination of toxoplasma antibodies is described. In 103 Finnish blood donors 27 had antibodies against Toxoplasma gondii. One donor had IgM antibodies and IgA antibodies were found in 9. In patients with acute toxoplasmosis a vigorous IgG antibody response resulted in high antibody levels soon after infection, declining gradually to mean adult levels in approximately 2 yr. IgM antibodies appeared during the earliest phases of infection and disappeared as early as in 1 or 2 months in some cases and in most cases by the 6th month after infection. An IgA antibody response was also always seen. It was slower than the IgM response and could therefore be used to improve the laboratory diagnosis especially in cases where IgM antibodies had already disappeared and no further increase in IgG antibodies could be detected.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6648374     DOI: 10.3109/inf.1983.15.issue-3.12

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  24 in total

1.  Toxoplasma gondii infection reveals a novel regulatory role for galectin-3 in the interface of innate and adaptive immunity.

Authors:  Emerson Soares Bernardes; Neide M Silva; Luciana Pereira Ruas; Jose Roberto Mineo; Adriano Motta Loyola; Daniel K Hsu; Fu-Tong Liu; Roger Chammas; Maria Cristina Roque-Barreira
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

2.  Bicentric evaluation of Access Toxo immunoglobulin M (IgM) and IgG assays and IMx toxo IgM and IgG assays and comparison with Platelia Toxo IgM and IgG assays.

Authors:  A Decoster; B Lecolier
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

3.  Immune response to oral polio vaccine in patients with IgA glomerulonephritis.

Authors:  P O Leinikki; J Mustonen; A Pasternack
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

4.  Public Health Laboratory Service enzyme linked immunosorbent assay for detecting Toxoplasma specific IgM antibody.

Authors:  R A Payne; D H Joynson; A H Balfour; J P Harford; D G Fleck; M Mythen; R J Saunders
Journal:  J Clin Pathol       Date:  1987-03       Impact factor: 3.411

5.  Effect of Toxoplasma gondii infection kinetics on trophoblast cell population in Calomys callosus, a model of congenital toxoplasmosis.

Authors:  E A V Ferro; D A O Silva; E Bevilacqua; J R Mineo
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

6.  Antibody reactivity to an Epstein-Barr virus BERF4-encoded epitope occurring also in Asp-57 region of HLA-DQ8 beta chain. Childhood Diabetes in Finland Study Group.

Authors:  P Parkkonen; H Hyöty; J Ilonen; H Reijonen; S Ylä-Herttuala; P Leinikki
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

7.  Platelia-Toxo IgA, a new kit for early diagnosis of congenital toxoplasmosis by detection of anti-P30 immunoglobulin A antibodies.

Authors:  A Decoster; B Slizewicz; J Simon; C Bazin; F Darcy; G Vittu; C Boulanger; Y Champeau; J L Demory; M Duhamel
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

8.  Determination of immunoglobulin M antibodies for hepatitis B core antigen with a capture enzyme immunoassay and biotin-labeled core antigen produced in Escherichia coli.

Authors:  P Vilja; H J Turunen; P O Leinikki
Journal:  J Clin Microbiol       Date:  1985-10       Impact factor: 5.948

9.  Humoral immunity against viral antigens in insulin-dependent diabetes mellitus (IDDM): altered IgA class immune response against mumps virus.

Authors:  H Hyöty; T Huupponen; P Leinikki
Journal:  Clin Exp Immunol       Date:  1985-04       Impact factor: 4.330

10.  Immunoblot analysis of Toxoplasma gondii antigens by human immunoglobulins G, M, and A antibodies at different stages of infection.

Authors:  P Partanen; H J Turunen; R T Paasivuo; P O Leinikki
Journal:  J Clin Microbiol       Date:  1984-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.